This company has been marked as potentially delisted and may not be actively trading. Ritter Pharmaceuticals (RTTR) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock RTTR vs. ABUS, TRVI, PHAR, ORGO, CRMD, CAPR, BCYC, KROS, AKBA, and COGTShould you be buying Ritter Pharmaceuticals stock or one of its competitors? The main competitors of Ritter Pharmaceuticals include Arbutus Biopharma (ABUS), Trevi Therapeutics (TRVI), Pharming Group (PHAR), Organogenesis (ORGO), CorMedix (CRMD), Capricor Therapeutics (CAPR), Bicycle Therapeutics (BCYC), Keros Therapeutics (KROS), Akebia Therapeutics (AKBA), and Cogent Biosciences (COGT). These companies are all part of the "medical" sector. Ritter Pharmaceuticals vs. Arbutus Biopharma Trevi Therapeutics Pharming Group Organogenesis CorMedix Capricor Therapeutics Bicycle Therapeutics Keros Therapeutics Akebia Therapeutics Cogent Biosciences Ritter Pharmaceuticals (NASDAQ:RTTR) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and community ranking. Which has more volatility and risk, RTTR or ABUS? Ritter Pharmaceuticals has a beta of -0.43, meaning that its stock price is 143% less volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500. Which has preferable valuation and earnings, RTTR or ABUS? Ritter Pharmaceuticals has higher earnings, but lower revenue than Arbutus Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRitter PharmaceuticalsN/AN/A-$10.13MN/AN/AArbutus Biopharma$6.17M112.01-$72.85M-$0.38-9.50 Is RTTR or ABUS more profitable? Ritter Pharmaceuticals has a net margin of 0.00% compared to Arbutus Biopharma's net margin of -1,137.65%. Ritter Pharmaceuticals' return on equity of 0.00% beat Arbutus Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Ritter PharmaceuticalsN/A N/A -162.05% Arbutus Biopharma -1,137.65%-68.18%-51.55% Do analysts prefer RTTR or ABUS? Arbutus Biopharma has a consensus target price of $5.50, indicating a potential upside of 52.35%. Given Arbutus Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Arbutus Biopharma is more favorable than Ritter Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ritter Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Arbutus Biopharma 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer RTTR or ABUS? Arbutus Biopharma received 134 more outperform votes than Ritter Pharmaceuticals when rated by MarketBeat users. Likewise, 70.66% of users gave Arbutus Biopharma an outperform vote while only 70.23% of users gave Ritter Pharmaceuticals an outperform vote. CompanyUnderperformOutperformRitter PharmaceuticalsOutperform Votes30270.23% Underperform Votes12829.77% Arbutus BiopharmaOutperform Votes43670.66% Underperform Votes18129.34% Do institutionals and insiders believe in RTTR or ABUS? 0.8% of Ritter Pharmaceuticals shares are owned by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are owned by institutional investors. 15.4% of Ritter Pharmaceuticals shares are owned by insiders. Comparatively, 20.3% of Arbutus Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media favor RTTR or ABUS? In the previous week, Arbutus Biopharma had 5 more articles in the media than Ritter Pharmaceuticals. MarketBeat recorded 5 mentions for Arbutus Biopharma and 0 mentions for Ritter Pharmaceuticals. Arbutus Biopharma's average media sentiment score of 0.90 beat Ritter Pharmaceuticals' score of 0.00 indicating that Arbutus Biopharma is being referred to more favorably in the news media. Company Overall Sentiment Ritter Pharmaceuticals Neutral Arbutus Biopharma Positive SummaryArbutus Biopharma beats Ritter Pharmaceuticals on 12 of the 16 factors compared between the two stocks. Get Ritter Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RTTR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RTTR vs. The Competition Export to ExcelMetricRitter PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$165.23M$6.69B$5.47B$7.92BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-5.597.3222.5118.54Price / SalesN/A241.49397.62103.35Price / CashN/A65.8538.1834.62Price / Book35.806.486.734.25Net Income-$10.13M$143.41M$3.22B$248.18M Ritter Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RTTRRitter PharmaceuticalsN/A$3.58+2.9%N/A+1,079.7%$165.23MN/A-5.597ABUSArbutus Biopharma2.0078 of 5 stars$3.34+1.5%$5.50+64.7%+30.0%$639.54M$6.17M-7.7790Positive NewsTRVITrevi Therapeutics3.6041 of 5 stars$6.59+1.9%$17.56+166.5%+135.8%$637.13MN/A-14.9820Upcoming EarningsNews CoveragePositive NewsPHARPharming Group2.5184 of 5 stars$8.75+2.8%$30.00+242.9%-6.6%$595.27M$297.20M-33.65280Upcoming EarningsShort Interest ↓News CoveragePositive NewsORGOOrganogenesis3.4236 of 5 stars$4.67+2.4%$5.50+17.8%+108.9%$592.29M$482.04M-77.83950Upcoming EarningsNews CoveragePositive NewsCRMDCorMedix2.5018 of 5 stars$9.06-0.4%$14.50+60.0%+74.9%$590.55M$43.47M-11.1930Upcoming EarningsPositive NewsCAPRCapricor Therapeutics1.8613 of 5 stars$12.83-1.5%$34.50+168.9%+141.0%$586.04M$22.27M-12.10N/ANews CoveragePositive NewsBCYCBicycle Therapeutics3.0381 of 5 stars$8.40-0.2%$29.14+246.9%-63.5%$581.30M$35.28M-2.55240Short Interest ↓Positive NewsKROSKeros Therapeutics3.0986 of 5 stars$14.26+0.4%$40.33+182.8%-74.4%$578.41M$3.55M-2.74100Upcoming EarningsPositive NewsAKBAAkebia Therapeutics4.0781 of 5 stars$2.43+2.1%$6.63+172.6%+91.3%$574.04M$160.18M-10.56430Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoveragePositive NewsGap UpCOGTCogent Biosciences2.1891 of 5 stars$4.91+5.8%$14.43+193.9%-19.8%$559.03MN/A-1.9880Upcoming EarningsOptions VolumeAnalyst Revision Related Companies and Tools Related Companies Arbutus Biopharma Competitors Trevi Therapeutics Competitors Pharming Group Competitors Organogenesis Competitors CorMedix Competitors Capricor Therapeutics Competitors Bicycle Therapeutics Competitors Keros Therapeutics Competitors Akebia Therapeutics Competitors Cogent Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RTTR) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredMassive dollar overhaul underway in D.C.?Trump's plan to save the U.S. Dollar The U.S. Dollar is crashing, and our reserve currency status is now in...Stansberry Research | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ritter Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Ritter Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RTTR Stock Free RTTR Stock Alerts